UNSPSC 51171701: Difenoxin

This classification denotes an antidiarrheal agent with the molecular formula C28H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3ZZ5BJ9F2Q, chemically known as 4-piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl- but generally known as difenoxin, which bears US NIH Compound Identifier 34328. European Medicines Agency schedules Difenoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07123MIG.

UNSPSC 51171701 Difenoxin (Commodity) encompasses controlled pharmaceutical products and active pharmaceutical ingredients procured by state and local government agencies, principally for substance-abuse testing, criminal-justice supervision, and public-health programs. State and local buyers under this code include community-supervision and corrections departments, state health and human services commissions, and cooperative purchasing consortia representing multiple state and local jurisdictions. The scope of work reflects two distinct procurement patterns: direct procurement of pharmaceutical testing and monitoring services for offender populations, and indirect procurement through pharmaceutical supply agreements that include controlled substances among broader multi-source generic and OTC product catalogs. Recent activity shows both compliance-driven specimen collection and drug-testing services and strategic pharmaceutical supply-chain sourcing through cooperative purchasing vehicles.

Activity is concentrated in Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department posted RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026), with an estimated contract value of $600,000 and a two-year base term plus three optional one-year renewals, encompassing approximately 25,031 annual tests across five-panel, six-panel, and ancillary testing at two collection sites in Plano and McKinney. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling state-level procurement strategy development around pharmaceutical distribution outside traditional PBM channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (proposals due March 26, 2026), with contracts effective July 1, 2026 and pricing weighted 75 percent on cost competitiveness; participating jurisdictions include Minnesota, Oregon, and other MMCAP members. None of the recent opportunities disclosed specific funding allocations or award values for difenoxin itself, and the code shows limited direct activity specific to controlled substances procurement outside the broader pharmaceutical-supply context.